SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-22-000054
Filing Date
2022-06-08
Accepted
2022-06-08 16:41:13
Documents
12
Period of Report
2022-06-03
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20220603.htm   iXBRL 8-K 40599
  Complete submission text file 0001720725-22-000054.txt   180638

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220603.xsd EX-101.SCH 1917
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220603_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220603_pre.xml EX-101.PRE 13053
6 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220603_htm.xml XML 11265
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 221003966
SIC: 2836 Biological Products, (No Diagnostic Substances)